Systems Biology in Drug Discovery and Development - gebonden uitgave, pocketboek

EAN (ISBN-13): 9780470261231
ISBN (ISBN-10): 0470261234
Gebonden uitgave
Verschijningsjaar: 20120615
Uitgever: Wiley
376 Bladzijden
Gewicht: 0,697 kg
Taal: Englisch

Boek bevindt zich in het datenbestand sinds 2011-04-04T02:30:51+02:00 (Amsterdam)
Detailpagina laatst gewijzigd op 2023-07-26T12:40:28+02:00 (Amsterdam)
ISBN/EAN: 9780470261231

ISBN - alternatieve schrijfwijzen:
0-470-26123-4, 978-0-470-26123-1
alternatieve schrijfwijzen en verwante zoekwoorden:
Auteur van het boek: seth, michels, john young, michelson
Titel van het boek: development, discovery, seth buch, systems biology, systems art

---

Gegevens van de uitgever

Auteur: Daniel L. Young; Seth Michelson
Titel: Wiley Series on Technologies for the Pharmaceutical; Systems Biology in Drug Discovery and Development
Uitgeverij: John Wiley & Sons
376 Bladzijden
Verschijningsjaar: 2011-11-18
Gewicht: 0,693 kg
Taal: Engels
112,00 € (DE)
No longer receiving updates
163mm x 235mm x 26mm

BB; gebunden; Hardcover, Softcover / Chemie; Medizinische Chemie, Pharmazeutische Chemie; Drug Discovery & Development; Bioinformatik; Bioinformatik u. Computersimulationen in der Biowissenschaften; Pharmazeutische Chemie; Life Sciences; Biowissenschaften; Pharmakologie u. Pharmazeutische Medizin; Wirkstoffforschung; Pharmacology & Pharmaceutical Medicine; Wirkstoffforschung u. -entwicklung; Medical Science; Bioinformatics & Computational Biology; Chemie; Medizin; Chemistry; Wirkstoffforschung u. -entwicklung; Pharmakologie u. Pharmazeutische Medizin; Bioinformatik u. Computersimulationen in der Biowissenschaften

Part I: Introduction to Systems Biology Approach. Chapter 1. Introduction to systems biology in drug discovery and development. 1.1 Introduction. Chapter 2. Methods for In Silico Biology: Model Construction and Analysis. 2.1 Introduction. 2.2 Model building. 2.3 Parameter estimation. 2.4. Model analysis. 2.5 Conclusions. Chapter 3. Methods in In Silico Biology: Modeling Feedback Dynamics in Pathways. 3.1 Introduction. 3.2 Statistical modeling. 3.3 Mathematical modeling. 3.4 Feedback and feedforward. 3.5 Conclusions. Chapter 4. Simulation of Population Variability in Pharmacokinetics. 4.1 Introduction. 4.2 PBPK modeling. 4.3 Simulation of pharmacokinetic variability. 4.4 Conclusions and future directions. Part II: Applications to Drug Discovery. Chapter 5. Applications of Systems Biology Approaches to Target Identification and Validation in Drug Discovery. 5.1 Introduction. 5.2 Typical drug discovery paradigm. 5.3 Integrated drug discovery. 5.4 Drivers of the disease phenotype: clinical endpoints and hypotheses. 5.5 Extracellular disease drivers: mechanistic biotherapeutic models. 5.6 Relevant cell models for clinical endpoints. 5.7 Intracellular disease drivers: signaling pathway quantification. 5.8 Target selection: dynamic pathway modeling. 5.9 Conclusions. Chapter 6. Lead Identification and Optimization. 6.1 Introduction. 6.2 The systems biology toolkit. 6.3 Conclusions. Chapter 7. The role of core biological motifs in dose-response modeling: an example with switch-like circuits. 7.1 Introduction: systems perspective in drug discovery. 7.2 Systems biology and toxicology. 7.3 Mechanistic/computational concepts in a molecular/cellular context. 7.4 Response motifs in cell signaling and their role in dose response. 7.5 Discussion and conclusions. Chapter 8. Mechanism Based Pharmacokinetic-Pharmacodynamic Modeling During Discovery and Early Development. 8.1 Introduction. 8.2 Challenges in drug discovery and development: the need to bring together PK and PD. 8.3 Methodological aspects and concepts. 8.4 Application during lead optimization. 8.5 Application during clinical candidate selection. 8.6 Entry into human (EIH) preparation and translational PK/PD modeling. 8.7 PK/PD for toxicology study design and evaluation. 8.8 Justification of starting dose, calculation of safety margins, and support of phase I design. 8.9 Phase I and beyond. 8.10 Support of early formulation development. 8.11 Outlook and conclusions. Part III: Applications to Drug Development. Chapter 9. Developing Oncology Drugs Using Virtual Patients of Vascular Tumor Diseases. 9.1 Introduction. 9.2 Modeling angiogenesis. 9.3 Use of rigorous mathematical analysis for gaining insight on drug development. 9.4 Use of angiogenesis models in theranostics. 9.5 Use of angiogenesis models in drug salvage: the virtual patient technology. 9.6 Summary and conclusions. Chapter 10. Systems Modeling Applied to Candidate Biomarker Identification. 10.1 Introduction. 10.2 Biomarker discovery approaches. 10.3 Examples of systems modeling approaches for identification of candidate biomarkers. 10.4 Conclusions. Chapter 11. Simulating Clinical Trials. 11.1 Introduction. 11.2 Types of models used in clinical trial design. 11.3 Sources of prior information for designing clinical trials. 11.4 Aspects of a trial to be designed and optimized. 11.5 Trial simulation. 11.6 Optimizing designs. 11.7 Real world examples. 11.8 Conclusions. Part IV: Synergies with other technologies. Chapter 12. Pathway Analysis in Drug Discovery. 12.1 Introduction: pathway analysis, dynamic modeling, and network analysis. 12.2 Software systems for pathway analysis. 12.3 Pathway analysis in modern drug development pipeline. 12.4 Conclusions. Chapter 13. Functional mapping for predicting drug response and enabling personalized medicine. 13.1 Introduction. 13.2 Functional mapping. 13.3 Predictive modeling. 13.4 Future directions. Chapter 14. Future Outlook of Systems Biology. 14.1 Introduction. 14.2 Systems complexity in biological systems. 14.3 Models for quantitative integration of data. 14.4 Changing requirements for systems approaches during drug discovery and development. 14.5 Better models for better decisions. 14.6 Advancing personalized medicine. 14.7 Improving clinical trials and enabling more complex treatment approaches. 14.8 Collaboration and training for systems biologists. 14.9 Conclusions.